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Undesirable drug interaction
in palliative medicine
Abstract
The importance of drug interactions in palliative care is acquiring more and more practical importance. In the
polytherapy used in palliative care, drugs can induce a number of interactions and increase the risk of
unwanted drug reactions.
This paper discusses the importance of drug-drug interactions in clinical practice.
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Introduction
The importance of the interaction of the drugs
used in palliative medicine is acquiring more and
more practical importance. The patient with advanced
disease often obtains a few drugs at the same time,
which may enter into unfavourable interactions, both
pharmacokinetic and pharmacodynamic, resulting in
undesirable consequences. Another practical prob-
lem is the fact that drugs administered simultaneously
may have a shared profile of undesirable effects with
the capacity to increase.
The general condition of the patient with ad-
vanced disease repeatedly undergoes dynamic
changes, which cause new symptoms to appear.
Thus, distinguishing which of the symptoms is the
result of the progression of the disease and which
may result directly from the undesirable effects of
the drugs used is an important element in evaluat-
ing the patient's status.
Palliative patients were once frequently treated
with chemo- and hormonotherapy, which may im-
pair organ functions crucial for the pharmacokinet-
ics of drugs. The occurrence of undesirable post-
drug effects is an additional risk factor. Hypoalbu-
minaemia is observed in the majority of patients,
which is important in drugs with a close affinity to
albumins. In such situations, a free drug fraction
increase is observed in the drugs, which increases
the risk of undesirable effects.
Interaction with drugs used
in palliative pain therapy
Interactions with non-steroidal
anti-inflammatory drugs (NSAIDs)
Non-steroidal anti-inflammatory drugs are one
of the most frequently used type of drug in pallia-
tive medicine. With regard to how they suppress
prostaglandin synthesis, they may enter into un-
favourable pharmacodynamic interaction with drugs
used in the pharmacotherapy of cardiovascular sys-
tem diseases (angiotensin-converting enzyme inhib-
itors, AT1 receptor antagonists, beta-adrenolytics,
Advances in Palliative Medicine 2008, vol. 7, no. 2
www.advpm.eu82
especially carvedilol and nebivolol), loop diuretics,
and the result of this interaction is to limit the effec-
tiveness of circulatory drugs and diuretics [1]. It is
worth mentioning that patients with impaired re-
nal function who take NSAIDs and loop diuretics
simultaneously have an increased risk of nephrotox-
icity.
It is important for the risk of interaction that the
majority of NSAIDs bind with blood proteins to a
high degree (over 90%). Consequently, special care
should be taken when simultaneously using other
drugs (sulphonylourea derivatives, oral anticoagu-
lants, or anti-epileptics) which bear a NSAID-like
affinity for albumins. The clinical effect of these in-
teractions is an increase in the free fraction of drugs
displaced by NSAIDs and the occurrence of undesir-
able effects.
A frequent mistake observed in clinical practice
is the simultaneous administration of two or even
more NSAIDs. It should be remembered that this
does not lead to the synergism of an analgesic ef-
fect but significantly increases the risk of gastrointes-
tinal toxicity, and liver and kidney damage. One of
the major undesirable effects of NSAIDs is drug-
induced gastropathy. This risk increases when the
patient simultaneously takes other drugs which may
damage the upper part of the digestive tract, in
particular:
— glucocorticosteroids;
— oral bisphosphonates;
— oral anticoagulants;
— drugs from the group of serotonin reuptake in
hibitors, which not only inhibit the reuptake of
serotonin in the structures of the central ner-
vous system but also suppress this uptake to
platelets;
— spironolactone, which inhibits fibrosis processes
that accompany the healing of digestive tract
damage and are induced by NSAIDs.
Moreover, the combination of NSAIDs with
spironolactone may cause hyperkalaemia.
The use of drugs from the H2 receptor antago-
nist group while NSAIDs are administered is a mis-
take. H2 blockers do not protect the digestive tract
from being damaged by NSAIDs but mask the symp-
toms of this damage [2].
In a clinical situation, when the administration
of gastric acid secretion inhibiting drugs together
with NSAIDs is necessary, proton pump inhibitors
are the best choice.
Care in the use of NSAIDs should be taken in
patients with liver damage because these drugs may
induce oxidative stress in hepatocytes, cause dam-
age to the mitochondria and apoptosis of hepato-
cytes. Diclofenac may directly damage hepatocytes,
which should be considered if the patient requires
other potentially hepatotoxic drugs.
With patients aged 65 and older, NSAIDs should
be very cautiously coadministered with angiotensin-
converting enzyme inhibitors and loop diuretics be-
cause this combination in such patients leads to
renal function impairment. Caution should be used
during the co-administration of NSAIDs with anti-
platelet drugs, owing to the increased risk of blood
loss.
Some NSAIDs (diclofenac, ibuprofen, naproxen,
piroxicam) are actively metabolized by the CYP2C9
isoenzyme: their use introduces an increased risk of
pharmacokinetic interaction with other drugs which
inhibit or activate this isoenzyme.
The most frequently used drugs in clinical prac-
tice which induce the activity of the CYP2C9 isoen-
zyme are presented in Table 1 [3]. Drugs that sup-
press its activity, and thus extend the half-life of
the above-mentioned NSAIDs, are presented in Ta-
ble 2.
Interactions with metamizole
Metamizole should be cautiously co-adminis-
tered with neuroleptics and phenothiazine deriva-
tives due to the risk of severe hyperthermia.
Metamizole increases the concentration of meth-
otrexate in blood serum, increasing its toxicity. Re-
cent literature suggests that metamizole can induce
the CYP3A4 isoenzyme , which means that it could
decrease the effectiveness of the metabolism of
drugs such as some benzodiazepines, tramadol,
Table 2.  Drugs inducing CYP2C9 activity
Drugs
Cyclofosfamide
Ifosfamide
Valproic acid
Table 1. Drugs suppressing CYP2C9 activity
Drugs
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Amiodarone
Anastrozole
Cimetidine
Ranitidine
Clopidogrel
Fluconazole
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codeine, fentanyl, methadone, paracetamol and glu-
cocorticosteroids.
Interactions with paracetamol
Paracetamol is metabolized by the 1A2 isoen-
zyme of P450 cytochrome. For this reason it should
be cautiously co-administered with drugs which in-
hibit the activity of this isoenzyme. This is of special
practical importance when co-administered with
ciprofloxacin, erythromycin, fluvoxamine and ticlo-
pidine. Paracetamol increases the kidney's elimina-
tion of prostaglandins and decreases plasma renin
activity. Consequently, it may imitate the diuretic
effect of loop diuretics.
Interactions with codeine
Codeine co-administered with hypnotics, tricyclic
antidepressants, mianserin, mirtazapine, trazodone,
benzodiazepines and neuroleptics has a synergistic
depressive influence on the central nervous system.
When simultaneously administered with other opio-
ids, the risk of respiratory depression increases.
Codeine undergoes hepatic metabolism under
the influence of the 2D6 and 3A4 isoenzymes of
P450 cytochrome. For this reason, caution should
be taken when co-administering drugs inhibiting
the activity of the above-mentioned isoenzymes.
Drugs of the most clinical importance with the ca-
pacity to inhibit CYP2D6 and CYP3A4 isoenzymes
are presented in Table 3.
Interactions with tramadol
Tramadol undergoes hepatic metabolism un-
der the influence of the CYP2D6 isoenzyme. As a
result, the pharmacologically active metabolite O-
demethyl tramadol (M1) is formed. For this rea-
son, the simultaneous administration of tramadol
with drugs inhibiting the activity of CYP2D6 (Table
3) is not recommended: on the one hand it inhibits
the formation of the active metabolite but on the
other it may lead, especially when forms with pro-
longed action are used, to undesirable and even
toxic symptoms. We must bear in mind that 5–10%
of the Caucasian population slowly metabolize drugs
with the CYP2D6 isoenzyme, and thus in these pa-
tients the risk of undesirable pharmacokinetic inter-
actions is additionally increased. Tramadol, apart
from its influence on opioid receptors, also inhibits
serotonin reuptake in the descending antinocicep-
tive system, which causes an increased risk of sero-
tonin syndrome.
Caution should be taken when co-administering
tricyclic antidepressants (amitriptyline in particular)
and serotonin reuptake inhibitors (fluoxetine and
paroxetine in particular), because while such a com-
bination inhibits the metabolism of tramadol, it also
increases the risk of seizure and serotonin syndrome.
The use of metoclopramide as an antiemetic dur-
ing tramadol therapy is also unfavourable. Meto-
clopramide is a strong inhibitor of tramadol metab-
olism.
Tramadol increases the depressive action of hyp-
notics, benzodiazepine derivatives and neuroleptics
on the CNS. When co-administered with neuroleptics,
it may cause seizures. Using tramadol with hypoten-
sive drugs increases the risk of hypotension [4].
Interactions with nefopam
Nefopam should not be used with tricyclic anti-
depressants because of the risk of hyperthermia,
severe hypertension and arrhythmia. Nefopam in-
hibits serotonin and noradrenalin reuptake and for
this reason increases the potency of cholinolytic and
sympathomimetic drugs.
Reserpine-containing drugs (Normatens) inhibit
the analgesic action of nefopam.
Drugs should be used cautiously with benzodi-
azepine derivatives, hypnotics and first-generation
antihistamine drugs.
Interactions with buprenorphine
Buprenorphine increases the depressive influence
of tricyclic antidepressants and neuroleptics on the
CNS. Used with other opioids, it increases the risk
of depression of the central nervous system. By de-
creasing saliva secretion, cholinolytic drugs may
hamper sublingual administration.
Table 3.  Drugs suppressing CYP2D6 and CYP3A4
activity
CYP2D6 CYP3A4
Metoclopramide serotonin reuptake inhibitors:
Amitriptyline fluoxetine, paroxetine, sertraline
Bupropion Ciprofloxacin
Fluoxetine Norfloxacin
Paroxetine Clarithromycin
Venlafaxine Erythromycin
Haloperidol Ketoconazole
Risperidone Itraconazole
Thioridazine Anastrozole
Doxorubicin Cisapride
Lanzoprazole Diltiazem
Methadone Methadone
Valproic acid Methylprednisone
Valproic acid
Werapamil
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Interactions with dihydrocodeine
Dihydrocodeine should be used cautiously in
patients taking MAO inhibitors. In people with ge-
netically determined rapid drug metabolism, simul-
taneous Quinidine administration decreases the an-
algesic effect of the drug.
Interactions with morphine
Morphine acts synergistically with drugs with a
depressive action on the central nervous system.
Morphine increases the action of anticoagulants.
Morphine is metabolized by UDPG 2D7 and CYP2D6
isoenzyme of P450 cytochrome and its metabolism
can be inhibited by CYP2D6 inhibitors  (see Table
3). As a result of morphine metabolism, the risk of
undesirable effects is increased [5].
Metoclopramide increases morphine absorption
from the digestive tract and intensifies its sedative
effect. Tricyclic antidepressants, clomipramine and
amitriptyline in particular, cause the prolongation
of the half-life of morphine. Morphine and cimeti-
dine preparations should not be administered si-
multaneously because of the increased risk of respi-
ratory depression, as cimetidine can inhibit mor-
phine metabolism.
Caution should be taken when simultaneously
administering morphine and benzodiazepines be-
cause this combination increases the risk of respira-
tory depression. This concerns the co-administra-
tion of morphine and alprazolam in particular, which
introduces analgesic action via an opioid receptor
of the mu type.
Interactions with fentanyl
Fentanyl increases the depressive influence of
hypnotics on the CNS, sedatives, benzodiazepine
derivatives and antihistamine drugs transferring to
the CNS. Fentanyl is metabolized by the 3A4 isoen-
zyme and drugs which inhibit the activity of this
isoenzyme can increase the risk of adverse drug re-
actions (see Table 3).
Interactions with methadone
Methadone is metabolized by the CYP 3A4 isoen-
zyme, hence caution should be taken when com-
bining drugs inhibiting its activity (Table 3). Metha-
done metabolism inhibition may cause bradycar-
dia, mood swings, depression of the respiratory cen-
tre and an increased risk of potentially lethal ar-
rhythmia, which are linked to QT prolongation in
ECG.
Methadone should be cautiously combined with
benzodiazepine derivatives due to the significant
toxicity of this mixture and the increased risk of
bradycardia, sleep disruption, depression, urinary
retention and the depression of cough and respira-
tory centres.
Caution should also be used when co-adminis-
tering methadone with tricyclic antidepressants
(TCA) because methadone disturbs their metabo-
lism, inhibiting the activity of the CYP 2D6 isoen-
zyme.
However, barbiturates, carbamazepine, rifampi-
cin, risperidone and glucocorticosteroids suppress
the analgesic action of methadone, probably be-
cause of interactions with CYP3A4.
Methadone may disrupt the metabolism of beta-
adrenolytics, neuroleptics and weak opioids (co-
deine, dihydrocodeine, tramadol), increasing the risk
of undesirable effects [6].
Interactions with ketamine
Ketamine increases the activity of myorelaxants.
It should be co-administered cautiously with alpha
and beta adrenolytics and calcium antagonists, ben-
zodiazepine derivatives and opioids, due to the risk
of heart failure.
Ketamine used with aminophilin decreases the
convulsant threshold.
Interactions with dextromethorphan
Dextromethorphan is metabolized with the CYP
2D6 isoenzyme and its use with drugs inhibiting
the activity of this isoenzyme (Table 3) increases the
risk of respiratory depression, nausea and dizziness.
Dextromethorphan intensifies the effects of sed-
atives, hypnotics, neuroleptics and benzodiazepine
derivatives on the CNS structures.
Interactions with amantadine
Amantadine increases the undesirable effects of
anticholinergic drugs, you need a conjunction here
to link these statements cotrimoxazol decreases the
renal clearance of amantadine, increasing the risk
of undesirable effects. Hydrochlorothiazide increas-
es plasma amantadine concentration.
Interactions with antidepressants used in
pain pharmacotherapy
Of the antidepressants used in pain pharmaco-
therapy, tricyclic antidepressants, doxepin, mi-
anserin, mirtazapine and venlafaxine have found
clinical use.
The interactions with serotonin reuptake inhibi-
tors (SSRIs) will not be discussed further in this pa-
per, due to the minor importance of this group of
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drugs as co-analgesics. Interactions with antidepres-
sants that are important from a practical point of
view are shown in Table 4 [7].
Interactions with anti-convulsants used in
palliative care
Drugs of the greatest practical importance in
pain pharmacotherapy with neuropathic compo-
nents are valproic acid, carbamazepine, gabapen-
tin and pregabalin. Interactions with these drugs
are presented in Table 5.
Interactions with relaxants: hyoscine
butylbromide , papaverine, drotaverine
The cholinolytic effect of hyoscine is increased
by TCAs, benzodiazepines and neuroleptics. Hyos-
cine intensifies the effect of drugs causing CNS de-
pression and suppresses the effect of dopamine
Table 5.  Interaction with anti-convulsants used in pain pharmacotherapy
Drug Interaction with other simultaneously administered drugs
Valproic acid Valproic acid increases plasma carbamazepine concentration, carbamazepine decre-
ases plasma valproic acid concentration. Valproic acid increases the effect of  antide-
pressants, neuroleptics and oral anticoagulants. If co-administered with  clonazepam,
idiopathic epilepsy may occur. Should be cautiously administered with drugs bearing a
strong affinity for blood proteins, due to the ability to increase free drug fraction.
Carbamazepine Drugs whose concentration increases after simultaneous administration with carbam-
azepine, leading to an increase in the risk of unfavourable effects: verapamil, diltiazem,
fluoxetine and isoniazide. Carbamazepine may decrease the therapeutic effectiveness
of oral anticoagulants, clonazepam, alprazolam, corticosteroids, cyclosporine, digoxin,
doxycycline, oestrogens and gestagens. When co-administered with thiazides and/or
furosemide, hyponatraemia may occur. Theophylline decreases plasma carbamazepine
concentration. Carbamazepine acts synergistically with neuroleptics. However, it must
not be forgotten that the risk of toxicity increases with such a combination.
Gabapentin Hypnotics increase drowsiness and ataxia after gabapentin. Drugs from the antacid
group decrease gabapentin absorption from the digestive system. Morphine increases
gabapentin blood concentration.
Pregabalin Increases the effect of lorazepam.
Table 4.  Interactions with antidepressants
Drug/group of drugs Interaction with other simultaneously administered drugs
Tricyclic antidepressants (TCA) Amitriptyline and clomipramine, the most frequently used drugs from the TCA group,
are metabolized with the participation of multiple isoenzymes of P450 cytochrome.
Consequently, there is a significant risk of unfavourable pharmacokinetic interaction.
Amitriptyline is metabolized by 2D6, 3A4, 1A2, 2C9 and 2C19 isoenzymes, and
clomipramine with 3A4, 1A2, 2C19 isoenzymes. Drugs suppressing the activity of the
above-mentioned isoenzymes will inhibit the metabolism of TCAs, increasing the risk of
undesirable effects. TCAs may increase the potency of sympathomimetics, causing an
increase in blood pressure. Due to the strong cholinolytic effect, TCAs inhibits peristal
sis of the digestive tract and may thus impair the absorption of orally administered
drugs. Clomipramine, the most serotoninergic drug amongst TCAs, may be a cause of
serotonin syndrome as a result of pharmacodynamic interaction with other drugs that
increase serotoninergic transmission.
Doxepine Should not be co-administered with QT-prolonging drugs in ECG, as it increases the
risk of potentially lethal arrhythmia. Doxepine increases the depressive action of other
sedatives, anxiolytics, antidepressants and neuroleptics on the CNS.
Phenothiazine neuroleptics increase the cholinolytic effect of doxepine.
Mianserin Acts synergistically and depressively with anxiolytics, hypnotics and sedatives on theCNS.
Mirtazapine Increases the sedative effect of benzodiazepine derivatives.
Venlafaxine Metabolized by 2D6 and 3A4 isoenzymes of P450 cytochrome. Thus co-administration
with drugs inhibiting activity of these isoenzymes (Table 3) should be avoided. Caution
should be used in simultaneously administering venlafaxine with tramadol and other
drugs of serotoninergic effect due to an increased risk of serotonin syndrome.
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antagonists on intestinal peristalsis. Papaverine and
drotaverine may intensify the effect of hypotensive
drugs.
Interactions with neuroleptics
The most frequently used neuroleptics are halo-
peridol, levomepromazine and risperidone.
Interactions with haloperidol
Haloperidol increases the depressive action of
opioids, benzodiazepines, barbiturates and TCAs on
the CNS. Valproic acid and oral anticoagulants in-
tensify the effect of haloperidol. Haloperidol increas-
es the cholinolytic effect of other simultaneously
administered drugs. It increases the action of hy-
potensive drugs, except clonidine to which it acts
antagonistically.
As for hypotension in patients treated with ha-
loperidol, catecholamines should not be used due
to the risk of a paradoxical and further decrease of
blood pressure. Haloperidol should not be co-ad-
ministered with magnesium salts due to the risk of
respiratory depression and hypotension.
 Interactions with levomepromazine
Drugs of cholinolytic effect intensify the anti-
cholinergic effect of levomepromazine. CNS depress-
ing drugs, including opioids, co-administered with
levomepromazine introduce a synergic suppressing
effect on CNS functions. When co-administered with
hypotensive drugs it can cause orthostatic hypoto-
nia. Levomepromazine can induce unwanted drug
interactions with procholinergic drugs such as me-
toclopramide.
Interactions with risperidone
Risperidone can increase the effect of drugs that
have a depressing effect on the CNS. Carbamazepine
decreases plasma risperidone concentration. TCAs
and phenothiazines increase plasma risperidone
concentration, increasing the risk of undesirable ef-
fects. A similar effect is observed in fluoxetine and
paroxetine. Drugs in the form of oral solutions should
not be drunk with tea and drinks such as Coca-Cola,
because these drinks can decrease risperidone ab-
sorption from the gastrointestinal tract.
Interactions with glucocorticosteroids
Dexamethasone, methylprednisolone and pred-
nisone are metabolized with CYP 3A4, which can be
induced simultaneously by CYP 3A4 inducers. Glu-
cocorticosteroids suppress the effect of oral anti-
diabetics and anticoagulants. Combined with
NSAIDS, they increase the risk of bleeding in the
upper part of the digestive tract. When co-adminis-
tered with diuretics, they increase the loss of potas-
sium ions.
Barbiturates and anti-epileptics decrease the ef-
fect of glucocorticosteroids.
Interactions with drugs used in the
treatment of nausea and vomiting
Interactions with metoclopramide
Metoclopramide decreases (digoxin) or increas-
es (NSAIDs, paracetamol, cyclosporine, levodopa)
drug absorption from the digestive system. Due to
its central action, metoclopramide intensifies the
depressive action of benzodiazepine derivatives and
TCAs on the CNS. It may increase opioid analgesia.
Cholinolytic drugs decrease the effect of metoclo-
pramide. Metoclopramide is a strong inhibitor of
the 2D6 isoenzyme of P450 cytochrome and inhib-
its the metabolism of codeine and tramadol.
Interactions with thiethylperazine
Thiethylperazine increases CNS depression when
co-administered with benzodiazepine derivatives
and opioids.
Interactions with ondansetron, granisetron
and tropisetron
These do not enter into clinically important in-
teractions with other simultaneously administered
medications.
Interactions with bisphosphonates
(clodronate, pamidronate, zolendr-
onate) and calcitonin
Bisphosphonates co-administered with glucocor-
ticosteroids and calcitonin increase the risk of hy-
pocalcaemia. Oral bisphosphonates given with
NSAIDs increase the risk of damage to the upper
part of the digestive tract.
Calcitonin does not interact with other simulta-
neously administered drugs.
Conclusion
As presented above, appropriate polytherapy is
of key importance for pharmacotherapy in pallia-
tive medicine.
Prevention of unfavourable drug and post-drug
interactions should be an inseparable element of
responsible treatment.
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